NCT03226808View on ClinicalTrials.gov

Vivacit-E Post-market Follow-up Study

NAActive, not recruitingINTERVENTIONAL
Enrollment

258

Participants

Timeline

Start Date

October 1, 2013

Primary Completion Date

March 2, 2026

Study Completion Date

June 30, 2028

Conditions
OsteoarthritisAvascular Necrosis of Bone of HipPost-traumatic; ArthrosisCongenital Hip Dysplasia
Interventions
DEVICE

Vivacit-E Liner

All subjects enrolled will receive the Vivacit-E liner.

Trial Locations (5)

19107

Rothman Institute, Philadelphia

27599

Department of Orthopaedics University of North Carolina at Chapel Hill, Chapel Hill

28207

OrthoCarolina Research Institute, Charlotte

78751

Texas Institute for Hip and Knee Surgery, Austin

80134

Denver Hip and Knee, Inc., Parker

Sponsors

Lead Sponsor

Zimmer Biomet
All Listed Sponsors
lead

Zimmer Biomet

INDUSTRY

NCT03226808 - Vivacit-E Post-market Follow-up Study | Biotech Hunter | Biotech Hunter